srra day highlight signific progress made lead asset
rapidli advanc broad clinic program
demonstr rel clean safeti profil two phase i/ii trial
think de-risk asset safeti standpoint allow compani
expand trial genetically-select patient tumor type
two addit trial plan start shortli
four shot goal preliminari key valu inflect efficaci data expect
see favor risk-reward data readout
note oral inhibitor clinic develop
strategi solid tumor support strong scientif rational
complement encourag preclin competior clinic data
target data day manag went detail
moder replic stress function slow cell divis
allow dna damag repair certain tumor heighten level
replic stress depend upon creat wherebi loss
allow tumor divid dna damag repair
result tumor cell death
recal current evalu two phase trial
monotherapi combin therapi day compani
announc trial updat detail
includ tumor type previou aggreg enrol
patient previou moreov base new preclin
work compani announc intent begin two new trial
year one parpi resist tumor addit
immun checkpoint therapi result four program
sound biolog ration note potenti market opportun
like drug succe
target indic
tr target
monotherapi studi expand fifteen center
three recruit patient across uk consist two phase dose escal
phase final dose optim stage cohort expans phase on-going
recruit dose escal proceed multipl dose level
well-toler mg qd mg qd
dose escal phase patient treat increas level
maxim toler dose achiev compani report occur
result two gi-rel dose-limit toxic dlt manag note
dose would progress expans cohort portion trial
final stage determin whether qd bid prefer dose strategi
favor dose escal phase safeti profil major gr
commonli report report causal fatigu gi
diarrhea sae gr neutropenia probabl relat gr heart
failure/cardiomyopathi possibl relat studi pi note heart failur patient
sick rapidli progress evid cardiac complic arisen
treat patient
phase ii cohort expans portion studi expand includ sixth indic
ovarian cancer manag note gener data
demonstr signific anti-tumor activ profound surviv benefit
driven preclin model enrol increas cohort patient
previou cohort patient manag note look
patient driver mutat across gene class highli correl
replic stress believ like synthet lethal alongsid
inhibit preliminari data cohort expans phase expect
combotherapi studi evalu alongsid low-dos sub-
therapeut gemcitabin gem ribonucleotid reductas inhibitor induc replic stress
evalu whether synthet lethal achiev induc replic stress pair
alongsid inhibit monotherapi studi combo studi two stage
initi dose escal stage rapidli identifi cohort expans phase enrol
prospect screen patient one pre-determin driver mutat manag
note singl mutat need combo trial trial alreadi gem caus
combotherapi dose escal phase evalu safeti all-com non-select patient
underway rapidli increas dose alongsid gem
standard gem dose dlt report studi henc dose escal on-going
combotherapi safeti profil clean major report gr
commonli observ report causal diarrhea anemia
thrombocytopenia fatigu influenza-lik ill nausea neutropenia vomit one gr
treatment relat ae neutropenia observ mg mg gem
occur sinc gem dosag reduc final evid emerg
cumul toxic and/or declin toler observ cycl drug administ
support potenti extend dose
combotherapi cohort expans phase anticip begin
expand enrol patient four indic urotheli carcinoma small cell lung cancer
soft tissu sarcoma cervical/anogenit cancer previou patient two indic
expect updat studi
given limit exposur median cycl rang unselect patient popul
dose-escal phase manag note efficacy/act conclus
drug might earli princip investig pi trial dr udai banerji posit
page
overal safeti profil note given biolog ration compet data
inhibitor would surpris see efficaci agent
manag note tumor upregul defens mechan overcom parpi
make well-defin target parpi resist tumor valid clinic potenti
inhibit parpi resist tumor compani intend initi dual
trial recent agreement jannsen allow srra use niraparib parpi
trial note lilli buy bori evalu prexasertib
inhibitor alongsid olaparib parpi solid tumor provid valid
approach proof concept preclin data
alongsid inhbit result robust tumor growth inhibit see manag note
current final design clinic studi investig alongsid immun
checkpoint inhibitor combo therapi expect initi
class inhibit rais concern due histor issu cardiac tox believ
page
problem due earlier promiscu chemistri neither prexasertib
inhibitor develop roch rhhbi nr suffer cardiac tox
thu bit reassur class effect look across field
inhibitor see note data limit view
offer sever potenti advantag prexasertib rout administr oral
vs iv improv safeti fewer gr lack signific heme tox enhanc
select vs dual blockad note could contribut drug toxic
would impair abil healthi cell repair doubl strand break safeti inform see
prexasertib pediatr odac slide clinic data due advantag would
expect present clinic profil least line prexasertib better
file plan manag note posit preclin data
indic oral inhibitor could target tumor depend dna replic
machineri ind plan support phase i/ii trial colorect cancer
financi srra report net loss per share expens
 srra end cash manag
estim suffici fund oper model tweak reflect current spend rate
chang valuat methodolog npv-deriv pt compar analysis-deriv
pt increas pt reflect progress made compani
lead candid believ demonstr encourag well-toler
safeti profil vs compet drug de-risk candid safeti standpoint
posit efficaci data remain de-risk clinic develop
acknowledg limit cross-compani comparison compani
uniqu profil analysi may captur develop risk could differ
indication/drug believ collect compani
nlnk repres good group compar srra note srra trade
signific discount compar select peer group compani averag enterpris
valu compani vs ev srra impli pt srra
pipelin catalyst begin enrol prospect screen patient low dose
gem combotherapi trial combo therapi zejula data apr
phase efficaci data esmo oct
page
page
producteventtimingcomplet monotherapi dose escal enrol prospect screen patient combo trial identif combo w/ zejula aacrapr robust phase data two trial esmooct cohort expans phase initi phase ib/ii combotherapi trial alongsid i/o monotherapi cohort expans phase combotherapi dose escal enter clinic oncolog kinas inhibitor strh analysi compani inhibitor sierra oncolog inc
page
companytickerratingstock pricemarket capevsharescashdebtcalithera bioscienc oncolog inc mrtxbuy cover genet corporationnlnkbuy cover oncolog pt srra base averag ev factset compani reportscompar analysi sierra oncolog inc
page
oper loss incom expens netinterest fair valu prefer stock incom incom expens provis incom incom incom redempt valu redeem convert prefer convert prefer stock convert prefer stock loss attribut common ep basic averag share rais suntrust robinson humphrey compani report last updat mm sierra oncolog inc
sierra oncolog biotech compani focus develop novel therapi cancer
compani pipelin includ lead candid inhibitor preclin candid
kinas inhibitor target dna damag respons ddr
network current evalu two uk-bas phase trial solid tumor
expect enter clinic develop sierra oncolog found
headquart vancouv canada
sierra oncolog embark rebuild compani around novel oncolog asset target
dna damag respons ddr network compani advanc candid
inhibitor phase develop advanc solid tumor preliminari phase i/ii efficaci
data expect acknowledg limit data lead candid stage
develop believ investor overlook potenti upsid asset given
promis earli data inhibitor potenti market opportun like
drug succe target indic across multipl tumor type
expect share outperform clinic newsflow
valuat risk
pt srra base compar analysis-deriv pt believ collect
compani nlnk repres good group
compar srra note srra trade signific discount compar
select peer group compani averag enterpris valu compani vs
ev srra impli pt srra note potenti market opportun
like drug succe target indic
clinic and/or regulatori risk sierra oncolog clinical-stag biotech signific
invest risk given lack market product compani futur success highli
conting success solid tumor indic clinic and/
regulatori setback could signific neg impact stock price compani
competition/commerci risk sierra oncolog busi larg depend commerci
success cancer could face competit exist newer
emerg therapeut products/class unexpect advers event hamper accept
among physician patient
intellectu propreti risk sierra oncolog commerci success depend abil obtain
maintain ip product product candid core technolog compani unabl
secur maintain adequ patent product product durat exclus
product could significantli reduc
reimbursement/pr pressur drug-pric strategi recent come increas
scrutini lawmak far biotech compani abl set high price product
abil could moder go forward
compani mention note
compani buy john bori
yatin suneja herebi certifi view express research report accur reflect
person view subject compani secur also certifi
page
receiv direct indirect compens exchang express specif
recommend report
